Adoptive cell therapy with macrophage-drug conjugates facilitates cytotoxic drug transfer and immune activation in glioblastoma models
Science Translational Medicine · 2025
DOI: 10.1126/scitranslmed.adr4058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2025. Verfasst von Miaomiao Sun und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, 8091 Zurich, Switzerland. Hauptthemen laut MEDLINE: Glioblastoma, Macrophages, Antineoplastic Agents, Brain Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
The treatment of solid tumors faces substantial hurdles because of inadequate drug delivery and the immunosuppressive tumor microenvironment. To address these challenges, we developed a therapeutic platform using macrophages loaded with ferritin-drug conjugates, referred to as macrophage-drug conjugates (MDC), and applied it to glioblastoma, an immunologically cold solid tumor. MDC loaded with ferritin-conjugated monomethyl auristatin E enabled efficient, cell contact–dependent transfer of the payload by a mechanism involving transfer of iron-binding proteins, from either mouse or human macrophages preferentially into glioma cells. This targeted delivery and therapeutic efficacy was demonstrated across in vitro coculture systems, ex vivo assays using dissociated glioblastoma patient tumor samples, and in vivo using orthotopic glioblastoma mouse models, all while maintaining a favorable preclinical safety profile evidenced by minimal systemic toxicity and localized drug biodistribution. Beyond direct tumor cell killing leading to significant tumor regression and prolonged survival in these models, MDC therapy reprogrammed the immunosuppressive tumor microenvironment. Immune profiling by spectral flow cytometry revealed enhanced infiltration and activation of cytotoxic T lymphocytes and B lymphocytes while reducing immunosuppressive regulatory T cells. This culminated in a robust, durable, T cell–dependent antitumor immune response, the necessity of which was confirmed through studies in immunodeficient mouse models and by lymphocyte depletion, and which conferred protection against tumor rechallenge. The combined cytotoxic and immunomodulatory effects highlight the potential of MDC therapy as a promising strategy for glioblastoma treatment and support its further clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, 8091 Zurich, Switzerland.
- Cellis AG, 8002 Zurich, Switzerland.
- Center of Cellular Immunotherapies, Warsaw University of Life Sciences, 02-787 Warsaw, Poland.
- Innate Lymphoid Cells and Cancer, Institute of Experimental Immunology, University of Zurich, 8057 Zurich, Switzerland.
- Pediatric Molecular Neuro-Oncology Research, Division of Oncology, University Children's Hospital Zürich, 8008 Zürich, Switzerland.
- Functional Genomics Center Zurich, ETH/University of Zurich, 8057 Zurich, Switzerland.
ORCID-Profile: Miaomiao Sun, Maciej Bialasek, Maud Mayoux, Meng-Syuan Lin, Alicia Buck, Ilona Marszałek, Bartłomiej Taciak, Marcel Bühler, Daria Kurpiel, Julia Nowakowska, Jan Brancewicz, Konrad Gabrusiewicz, Sibylle Pfammatter, Steve Pascolo, Gregor Hutter, Lubomir Bodnar, Berend Snijder, Luca Regli, Michael Weller, Martin Baumgartner, Sonia Tugues, Tomasz P Rygiel, Magdalena Krol, Tobias Weiss
Zitieren
APA
Sun, M., Bialasek, M., Mayoux, M., Lin, M. S., Buck, A., Marszałek, I., Taciak, B., Bühler, M., Górczak, M., Kucharzewska, P., Kurpiel, D., Siemińska, M., Nowakowska, J., Brancewicz, J., Gabrusiewicz, K., Lipiński, W., Pfammatter, S., Pascolo, S., Hutter, G., …, & Weiss, T. (2025). Adoptive cell therapy with macrophage-drug conjugates facilitates cytotoxic drug transfer and immune activation in glioblastoma models. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adr4058
Vancouver
Sun M, Bialasek M, Mayoux M, Lin MS, Buck A, Marszałek I, et al. Adoptive cell therapy with macrophage-drug conjugates facilitates cytotoxic drug transfer and immune activation in glioblastoma models. Science Translational Medicine. 2025. doi:10.1126/scitranslmed.adr4058
BibTeX
@article{Sun2025,
author = {Sun, Miaomiao and Bialasek, Maciej and Mayoux, Maud and Lin, Meng-Syuan and Buck, Alicia and Marszałek, Ilona and Taciak, Bartłomiej and Bühler, Marcel and Górczak, Małgorzata and Kucharzewska, Paulina and Kurpiel, Daria and Siemińska, Małgorzata and Nowakowska, Julia and Brancewicz, Jan and Gabrusiewicz, Konrad and Lipiński, Waldemar and Pfammatter, Sibylle and Pascolo, Steve and Hutter, Gregor and Bodnar, Lubomir and Snijder, Berend and Regli, Luca and Weller, Michael and Baumgartner, Martin and Tugues, Sonia and Rygiel, Tomasz P and Krol, Magdalena and Weiss, Tobias},
title = {Adoptive cell therapy with macrophage-drug conjugates facilitates cytotoxic drug transfer and immune activation in glioblastoma models},
journal = {Science Translational Medicine},
year = {2025},
doi = {10.1126/scitranslmed.adr4058}
}
EUVIMED